Company Overview - Ai Mei Vaccine Co., Ltd. is the second-largest vaccine company in China, holding a market share of 7.4%, second only to the state-owned China National Pharmaceutical Group [2] - The company covers the entire value chain from research and development to manufacturing and commercialization [2] - It possesses five validated human vaccine platform technologies, including bacterial, viral, genetic engineering, combination, and mRNA vaccine technologies [2] Financial Performance - As of December 31, 2024, Ai Mei Vaccine reported total revenue of 1.285 billion yuan, a year-on-year increase of 8.22% [1] - The net profit attributable to shareholders was -277 million yuan, showing a significant year-on-year increase of 78.69% [1] - The gross profit margin stood at 74.2%, with a debt-to-asset ratio of 50.63% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.19 times, with a median of 6.44 times [1] - Ai Mei Vaccine's P/E ratio is -19.01 times, ranking 111th in the industry [1] - Other companies in the industry have P/E ratios such as: Qingdao Haier Biomedical (1.42), Kingsray Biotechnology (1.63), Dongrui Pharmaceutical (3.35), Jilin Changlong Pharmaceutical (5.94), and Dajiang International (6.94) [1] Recent Developments - The company is one of the first to receive a P3 laboratory construction license under China's 14th Five-Year Plan [2] - In response to the current pandemic, Ai Mei Vaccine is utilizing its comprehensive platform technology to develop new COVID-19 vaccines using three validated technological routes: mRNA, inactivated virus, and recombinant adenovirus vector [2]
艾美疫苗（06660.HK）8月5日收盘上涨8.41%，成交888.37万港元